重组人生长激素治疗新生儿败血症的临床研究

Clinical study on recombinant human growth hormone in treatment of neonatal sepsis

目的观察重组人生长激素治疗败血症患儿的临床疗效及对肌酸激酶同工酶(CK-MB)、肌酸磷酸激酶(CK)和血清炎症因子的影响。方法 2011年2月—2014年5月武警河北总队医院收治的败血症患儿80例,随机分为对照组和治疗组,每组40例。对照组给予综合治疗,同时给予抗生素治疗。治疗组患者入院第2天腹部sc注射用重组人生长激素,0.1 U/kg,隔日1次,其他治疗同对照组。两组均连续治疗10 d。比较两组的临床疗效,同时比较两组治疗前后CK-MB、CPK、中性粒细胞凝胶酶载脂蛋白(NGAL)、肿瘤坏死因子-α(TNF-α)以及胰岛素样生长因子-1(IGF-1)的变化。结果对照组和治疗组总有效率分别为77.5%、90.0%,两组比较差异有统计学意义(P<0.05)。治疗后,两组CK、CK-MB、NGAL、TNF-α、IGF-1水平均较治疗前明显下降,同组比较差异有统计学意义(P<0.05);且治疗组的改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。结论重组人生长激素治疗新生儿败血症有较好的临床疗效,可降低患儿心肌损伤,减轻全身炎症反应。

Objective To investigate the efficacy of recombinant human growth hormone（rh GH） in treatment of neonatal sepsis, the influences of recombinant human growth hormone about CK-MB, CK, and serum inflammatory factors. Methods Children（80 cases） with neonatal sepsis who came to the Armed Police Hebei Corps Hospital from February 2011 to May 2014 were randomly divided into the control and treatment groups, and each group had 40 cases. The patients in control group were given comprehensive treatment, and at the same time they were iv administered with corresponding antibiotics. The patients in treatment group were sc administered with Recombinant Human Growth Hormone for injection every other day, 0.1 U/kg, and other treatment was the same as the control group. The patients in the two groups were treated for 10 d. After the treatment, the efficacy was evaluated, at the same time the changes of CK-MB, CK, NGAL, TNF-α, and IGF-1 in two groups were compared. Results The efficacies in the control and treatment groups were 77.5% and 90.0%, respectively, and there were differences between two groups（P〈0.05）. After treatment, the levels of CK, CK-MB, NGAL, TNF-α, and IGF-1in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And the improvement degree of the treatment group was better than that in the control group, with significant differences between two groups（P〈0.05）. Conclusion Recombinant human growth hormone has the good clinical effect in treatment of neonatal sepsis, and can reduce myocardial injury, which can relieve systemic inflammatory response.